Affymetrix, Inc. announced that Timothy Barabe has been appointed Executive Vice President and Chief Financial Officer of the company. Barabe will lead the company’s financial functions as well as the treasury, investor relations, and information technology departments, reporting to Kevin King, President and Chief Executive Officer.

“Tim has a proven ability to translate business strategy into financial success, and I’m delighted that he will be joining my leadership team to help drive growth,” said King. “With his experience in the medical and life science sectors and passion for financial excellence, Tim is a natural fit for Affymetrix.”

Barabe joins Affymetrix with experience from top-tier pharmaceutical, medical, and emerging life science companies. Since 2006, he served as Senior Vice President and Chief Financial Officer at Human Genome Sciences. Previously, Barabe was Chief Financial Officer at Regent Medical Ltd. For more than 20 years, he held senior executive roles in finance, general management, and strategic planning at Novartis AG, the world’s sixth largest pharmaceutical company1. His roles included Chief Financial Officer of the Sandoz Generics Business Unit, President of the CIBA Vision Corporation Specialty Lens Business Franchise, and Group Vice President and Chief Financial Officer of CIBA Vision Corporation.

“Affymetrix is a pioneering brand with innovative new technologies,” said Barabe. “I’m extremely excited to join a team committed to financial strength and discipline. I look forward to working with the entire leadership team to focus on human health, driving results, and creating value for our shareholders.”

Barabe received his MBA in finance from the University of Chicago and his BBA in finance from the University of Massachusetts.

Barabe replaces John Batty, who served three years at Affymetrix and was instrumental in laying the foundation for the company’s long-term growth.

Date: March 15, 2010
Source: Affymetrix, Inc.